Showing 2 posts of 2 posts found.


AbbVie’s Aquipta receives MHRA marketing authorisation

September 5, 2023
Sales and Marketing AbbVie, Aquipta, MHRA, Neurology, atogepant, migraines

AbbVie has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorisation for Aquipta (atogepant), …


Lilly’s migraine drug succeeds in Phase 3 trials

May 15, 2017
Research and Development, Sales and Marketing Eli Lilly, migraines

Eli Lilly announced the successful results of three Phase 3 trials examining the benefits of its drug, galcanezumab, in patients …

Latest content